MyoCardioCare, Inc. Appoints Appoints Renowed Surgeon Dr. Gus Vlahakes to Scientific Advisory Board
ROCHESTER, NY, November 17, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announces the appointment of Dr. Gus J. Vlahakes to its Scientific Advisory Board. Dr. Vlahakes will be providing clinical guidance in the development of MyoCardioCare’s next-generation technologies.
He has been on the Staff at Massachusetts General Hospital for the last 25 years, and has been involved with mechanical circulatory support since 1987. He has been principle investigator on numerous clinical trials of circulatory support devices during his tenure on the staff at Massachusetts General Hospital.
John F. Lanzafame, President of MyoCardioCare, commented, “We are excited to welcome Dr. Vlahakes to MyoCardioCare’s Scientific Advisory Board. His leadership in the field of cardiac surgery and his extensive experience with circulatory support devices will provide great insight as we commercialize the MCC3000."
Dr. Vlahakes is an engineering graduate of MIT and received his MD degree from Harvard Medical School. He received his general surgery and cardiothoracic surgical training at Massachusetts General Hospital and Boston Children's Hospital. He completed a three-year cardiac physiology fellowship at the Cardiovascular Research Institute at the University of California, San Francisco.
Dr. Vlahakes is joined on the MyoCardioCare’s Scientific Advisory Board by Dr. Brian Gibler who was recently appointed President & CEO of the University of Cincinnati Hospital and Senior Vice President of UC Health.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
John Lanzafame, President
Phone: (877) 778-2696
Fax: (877) 778-2685